日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Oncogenic mechanism-based pharmaceutical validation of therapeutics targeting MET receptor tyrosine kinase

基于致癌机制的靶向MET受体酪氨酸激酶的药物验证

Yao, Hang-Ping; Tong, Xiang-Min; Wang, Ming-Hai

MET and RON receptor tyrosine kinases in colorectal adenocarcinoma: molecular features as drug targets and antibody-drug conjugates for therapy

MET和RON受体酪氨酸激酶在结直肠腺癌中的作用:作为药物靶点和抗体药物偶联物治疗的分子特征

Yao, Hang-Ping; Tong, Xiang-Min; Hudson, Rachel; Wang, Ming-Hai

Targeting RON receptor tyrosine kinase for treatment of advanced solid cancers: antibody-drug conjugates as lead drug candidates for clinical trials

靶向RON受体酪氨酸激酶治疗晚期实体瘤:抗体药物偶联物作为临床试验的先导候选药物

Yao, Hang-Ping; Suthe, Sreedhar Reddy; Tong, Xiang-Min; Wang, Ming-Hai

RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer

RON和MET共表达过表达是三阴性乳腺癌患者预后不良的重要病理特征,也是酪氨酸激酶抑制剂的治疗靶点

Weng, Tian-Hao; Yao, Min-Ya; Xu, Xiang-Ming; Hu, Chen-Yu; Yao, Shu-Hao; Liu, Yi-Zhi; Wu, Zhi-Gang; Tang, Tao-Ming; Fu, Pei-Fen; Wang, Ming-Hai; Yao, Hang-Ping

Correction to: Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy

更正:人源化抗体药物偶联物 Zt/g4-MMAE 靶向 RON 受体酪氨酸激酶用于癌症治疗的疗效、药代动力学特征和毒理学活性

Yao, Hang-Ping; Feng, Liang; Suthe, Sreedhar Reddy; Chen, Ling-Hui; Weng, Tian-Hao; Hu, Chen-Yu; Jun, Eun Sung; Wu, Zhi-Gang; Wang, Wei-Lin; Kim, Song Cheol; Tong, Xiang-Min; Wang, Ming-Hai

Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy

人源化抗体药物偶联物Zt/g4-MMAE靶向RON受体酪氨酸激酶用于癌症治疗的疗效、药代动力学特征和毒理学活性

Yao, Hang-Ping; Feng, Liang; Suthe, Sreedhar Reddy; Chen, Ling-Hui; Weng, Tian-Hao; Hu, Chen-Yu; Jun, Eun Sung; Wu, Zhi-Gang; Wang, Wei-Lin; Kim, Song Cheol; Tong, Xiang-Min; Wang, Ming-Hai

The optimum marker for the detection of lymphatic vessels

检测淋巴管的最佳标志物

Kong, Ling-Ling; Yang, Nian-Zhao; Shi, Liang-Hui; Zhao, Guo-Hai; Zhou, Wenbin; Ding, Qiang; Wang, Ming-Hai; Zhang, Yi-Sheng

Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer

对抗体-美登素偶联物作为靶向RON药物递送策略治疗非小细胞肺癌的生物学评价

Feng, Liang; Yao, Hang-Ping; Zhou, Yong-Qing; Zhou, Jianwei; Zhang, Ruiwen; Wang, Ming-Hai

Erratum to: Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer

勘误:抗体-美登素偶联物作为靶向RON药物递送策略治疗非小细胞肺癌的生物学评价

Feng, Liang; Yao, Hang-Ping; Sharma, Sharad; Zhou, Yong-Qing; Zhou, Jianwei; Zhang, Ruiwen; Wang, Ming-Hai

Ribosomal proteins and human diseases: pathogenesis, molecular mechanisms, and therapeutic implications

核糖体蛋白与人类疾病:发病机制、分子机制和治疗意义

Wang, Wei; Nag, Subhasree; Zhang, Xu; Wang, Ming-Hai; Wang, Hui; Zhou, Jianwei; Zhang, Ruiwen